Novartis (NVS) today announced that Cosentyx met the primary endpoint and all secondary endpoints in the Phase III REPLENISH trial. Cosentyx demonstrated statistically significant and clinically meaningful sustained remission vs placebo at Week 52 in adults with polymyalgia rheumatica. Data will be presented at an upcoming medical congress and submitted to health authorities in the first half of 2026. A key secondary endpoint of the REPLENISH trial was adjusted annual cumulative steroid dose through Week 52. Other secondary measures included complete sustained remission at Week 52, and time until patients needed additional treatment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Trump admin prepares new probe into U.S. pharma prices, FT says
- Novartis presents new Pluvicto data, showed improvement in rPFS
- Enliven, Novartis drugs poised to lead in CML markets, says Clear Street
- Novartis announces results from five-year analysis of NATALEE trial of Kisqali
- Novartis Scemblix receives positive CHMP opinion for Scemblix